Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Moebus V, Augustin D, Hoffmann G, Weiss E, Boehmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jaenicke F, Wallwiener D, Harbeck N, Kuhn W (2017)
Publication Type: Journal article
Publication year: 2017
Book Volume: 28
Pages Range: 2899-2899
Journal Issue: 11
APA:
Nitz, U., Gluz, O., Huober, J., Kreipe, H.H., Kates, R.E., Hartmann, A.,... Kuhn, W. (2017). Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014). Annals of Oncology, 28(11), 2899-2899. https://doi.org/10.1093/annonc/mdw349
MLA:
Nitz, U., et al. "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014)." Annals of Oncology 28.11 (2017): 2899-2899.
BibTeX: Download